Novel molecular targets for the therapy of urothelial carcinoma

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 5, 2012, Pages 499-513

  Jana, Bagi R P ^a   Galsky, Matthew D ^b   Hahn, Noah M ^c   Milowsky, Matthew I ^d   Sonpavde, Guru ^e,f  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b Mount Sinai Tisch Cancer Institute   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e TEXAS ONCOLOGY   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Novel molecular targets; Targeted therapy; Transitional cell carcinoma; Urothelial carcinoma

Indexed keywords

AFLIBERCEPT; BCG VACCINE; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CDX 1307; CETUXIMAB; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; DOCETAXEL; DOVITINIB; ERLOTINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GEFITINIB; GEMCITABINE; ICRUCUMAB; IPILIMUMAB; METHOTREXATE; PACLITAXEL; PROTEIN P53; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VINBLASTINE; VINFLUNINE; VOLASERTIB;

ADVANCED CANCER; ANGIOGENESIS; BLADDER CANCER; BLEEDING; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE SPECIFIC SURVIVAL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; HYPERTENSION; KARYOTYPING; LONG TERM CARE; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; REVIEW; SURVIVAL TIME; THROMBOEMBOLISM; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TUMOR SUPPRESSOR GENE; VISCERAL METASTASIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UROTHELIUM;

EID: 84860254010     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.677441     Document Type: Review

References (133)

1. Saxman SB, Propert KJ, Einhorn LH, et al. Long-Term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1997;15:2564-2569
2. Sternberg CN, De Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;42:50-54
3. von der Maase H, Sengelov L, Roberts JT, et al. Long-Term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602-4608
4. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. J Clin Oncol (Meeting Abstracts) 2007;25:LBA5030
5. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-866
6. Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-Term results of the BA06 30894 trial. J Clin Oncol 2011;29:2171-2177
7. Vale CL, Meta-Analysis Group, Medical Research Council Clinical Trials Unit, Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-Analysis of individual patient data advanced bladder cancer (ABC) meta-Analysis collaboration. Eur Urol 2005;48:202-5; discussion 205-6. 222 Euston Road, London NW1 2DA, UK
8. Sonpavde G, Goldman BH, Speights VO, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 2009;115:4104-4109
9. Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011;12:211-214
10. Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol 2011;29:2432-2438
11. Galsky MD, Chen GJ, Oh WK, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 2012;23(2):406-410
12. De Santis M, Bellmunt J, Mead G, et al. Randomized Phase II/III Trial assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC Study 30986. J Clin Oncol 2009;30:191-199
13. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27:4454-4461
14. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-Term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173-3181
15. Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2009;28:1850-1855
16. Escudero DO, Shirodkar SP, Lokeshwar VB. Bladder carcinogenesis and molecular pathways. Cancer Drug Discovery and Development 2011:23-41 DOI: 10.1007/978-1-60761-928-4-2
17. Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 2000;27:1-13; vii.
18. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-788
19. Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003;63:8108-8112
20. Tomlinson DC, Baldo O, Harnden P, et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007;213:91-98
21. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16:139-149
22. Fadl-Elmula I. Chromosomal changes in uroepithelial carcinomas. Cell Chromosome 2005;4:1
23. Knowles MA. Molecular subtypes of bladder cancer: jekyll and Hyde or chalk and cheese? Carcinogenesis 2006;27:361-373
24. Salinas-Sanchez AS, Lorenzo-Romero JG, Gimenez-Bachs JM, et al. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: A long-Term study. Urol Oncol 2008;26:620-626
25. Shariat SF, Lotan Y, Karakiewicz PI, et al. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol 2009;182:907-913
26. Miyamoto H, Shuin T, Ikeda I, et al. Loss of heterozygosity at the p53, RB, DCC and APC tumor suppressor gene loci in human bladder cancer. J Urol 1996;155:1444-1447
27. Wada T, Louhelainen J, Hemminki K, et al. Bladder cancer: Allelic deletions at and around the retinoblastoma tumor suppressor gene in relation to stage and grade. Clin Cancer Res 2000;6:610-615
28. Mitra AP, Pagliarulo V, Yang D, et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol 2009;27:3929-3937
29. Karam JA, Lotan Y, Karakiewicz PI, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007;8:128-136
30. Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004;22:1014-1024
31. Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. USA 2009;106:14016-21
32. He X, Marchionni L, Hansel DE, et al. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells 2009;27:1487-1495
33. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
34. Campbell SC, Volpert OV, Ivanovich M, et al. Molecular mediators of angiogenesis in bladder cancer. Cancer Res 1998;58:1298-1304
35. Wu X, Obata T, Khan Q, et al. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 2004;93:143-150
36. Oka N, Yamamoto Y, Takahashi M, et al. Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer. BJU Int 2005;95:660-663
37. Tomlinson DC, Lamont FR, Shnyder SD, et al. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-Activated protein kinase pathway in bladder cancer. Cancer Res 2009;69:4613-4620
38. Sanchez-Carbayo M, Socci ND, Lozano J, et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24:778-789
39. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009;23:675-680
40. Bartoletti R, Cai T, Nesi G, et al. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. J Surg Res 2007;143:422-427
41. Garcia-Closas M, Malats N, Real FX, et al. Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet 2007;3:e29
42. McConkey DJ, Lee S, Choi W, et al. Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol 2010;28:429-440
43. Kim WJ, Kim EJ, Jeong P, et al. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res 2005;65:9347-9354
44. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001;61:8659-8663
45. Muto S, Horie S, Takahashi S, et al. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res 2000;60:4021-4025
46. Allen LE, Maher PA. Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line. J Cell Physiol 1993;155:368-375
47. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997;57:5281-5285
48. Nakanishi R, Oka N, Nakatsuji H, et al. Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer. Urol Int 2009;83:98-106
49. Nguyen M, Watanabe H, Budson AE, et al. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 1993;85:241-242
50. O'Brien T, Cranston D, Fuggle S, et al. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995;55:510-513
51. Slaton JW, Millikan R, Inoue K, et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 2004;171:570-574
52. Quentin T, Schlott T, Korabiowska M, et al. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. Anticancer Res 2004;24:2745-2756
53. Bamias A, Kyriakou F, Chorti M, et al. Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/beta-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: A hellenic cooperative oncology group (HECOG) study. Anticancer Res 2008;28:2479-2486
54. Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol 2011;29:1525-1530
55. Balar AV, Milowsky MI, Apolo AB, et al. Phase II trial of gemcitabine, carboplatin, and bevacizumab in chemotherapy-naive patients (Pts) with advanced/metastatic urothelial carcinoma. J Clin Oncol 2011;29(suppl 7):abstract 248
56. Apolo AB, Regazzi AM, Milowsky MI, Bajorin DF. Memorial Sloan-Kettering Cancer Center, New York, NY: Vascular thromboembolic events in patients (pts) with advanced urothelial cancer (UC) treated with carboplatin/gemcitabine alone or in combination with bevacizumab. Presented at the 2009 ASCO Annual Meeting; 2009
57. Chaudhary UB, Golshayan AR, Brisendine A, et al. Phase II trial of neoadjuvant cisplatin, gemcitabine and bevacizumab followed by radical cystectomy (RC) in patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder [abstract 276]. Genitourinar cancer symposium; 2011
58. Siefker-Radtke AO, Kamat A, Corn PG, et al. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center. J Clin Oncol 2012;30(Suppl 5):abstract 261
59. Twardowski P, Stadler WM, Frankel P, et al. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology 2010;76:923-926
60. Sonpavde G, Jian W, Liu H, et al. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009;27:391-399
61. Bellmunt J, Gonzalez-Larriba JL, Prior C, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 2011;22:2646-2653
62. Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010;28:1373-1379
63. Grivas P, Nanus DM, Stadler WM, et al. Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC). J Clin Oncol 2012;30(Suppl 5):abstract 265
64. Galsky MD, Sonpavde G, Hellerstedt BA, et al. Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma. J Clin Oncol 2010;28:15s (suppl; abstr 4573)
65. Dreicer R, Li H, Stein M, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: A trial of the Eastern Cooperative Oncology Group. Cancer 2009;115:4090-4095
66. Sridhar SS, Winquist E, Eisen A, et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: A study of the PMH Phase II Consortium. Investigational new drugs 2011;29:1045-1049
67. Pili R, Qin R, Flynn PJ, et al. Roswell Park Cancer Institute, Buffalo, NY;Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI: MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Presented at the 2011 Genitourinary cancers symposium; 2011
68. Necchi A, Nicolai N, Ortega C, et al. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Institute for Cancer Research and Treatment, Turin, Italy; Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy;University Hospital of Udine, Udine, Italy: Updated results of INT70/09 phase II study of pazopanib (PZP) monotherapy for patients with relapsed/refractory urothelial cancer (UC). J Clin Oncol 2011;29(Suppl):abstract 4618
69. Choueiri TK, Ross RW, Jacobus S, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 2012;30(5):507-512
70. Lonn U, Lonn S, Friberg S, et al. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1995;1:1189-1194
71. Sriplakich S, Jahnson S, Karlsson MG. Epidermal growth factor receptor expression: Predictive value for the outcome after cystectomy for bladder cancer? BJU Int 1999;83:498-503
72. Gardmark T, Wester K, De la Torre M, et al. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int 2005;95:982-986
73. Adam L, Zhong M, Choi W, et al. miR-200 expression regulates epithelial-To-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009;15:5060-5072
74. Wong Y, Litwin S, Vaughn DJ, et al. Fox Chase Cancer Center, Philadelphia, PA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Pottstown Cancer Center, Pottstown, PA; Hematology Oncology Associates, Mt. Holly, NJ; Paoli Cancer Center, Paoli, PA; Fox Chase Extramural Research Network, Philadelphia, PA: Effect of EGFR inhibition with cetuximab (CET) on the efficacy of paclitaxel (TAX) in previously treated metastatic (MET) urothelial cancer. Presented at the ASCO 2011. J Clin Oncol 2011;29(Suppl):abstract 4617
75. Dominguez-Escrig JL, Kelly JD, Neal DE, et al. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 2004;10:4874-4884
76. Tiryakioglu Ok NO, Cakir OO, Tunali NE. Investigation of the EGFR gene variations in bladder cancer patients using INFINITITM Analyzer. J Cell Mol Biol 2011;9:83-86
77. Villares GJ, Zigler M, Blehm K, et al. Targeting EGFR in bladder cancer. World J Urol 2007;25:573-579
78. Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int 2010;105(3):317-321
79. Pruthi RS, Nielsen M, Heathcote S, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: Clinical and pathological results. BJU Int 2010;106:349-356
80. Pruthi RS, Nielsen M, Heathcote S, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: Clinical and pathological results. BJU Int 2010;106:349-354
81. Philips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: Results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 2009;20(6):1074-1079
82. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007;25:2218-2224
83. Wulfing C, Machiels JP, Richel DJ, et al. A single-Arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009;115:2881-2890
84. Pandith AA, Shah ZA, Siddiqi MA. Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer. Urol Oncol 2010 Available online 6 September 2010. PMID: 20822928
85. Qing J, Du X, Chen Y, et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Investig 2009;119:1216-1229
86. Miyake M, Ishii M, Koyama N, et al. 1-Tert-butyl-3-[6-(3,5-dimethoxy- phenyl)-2-(4-diethylamino-butylamino)-pyr ido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. J Pharmacol Exp Ther 2010;332:795-802
87. Lamont FR, Tomlinson DC, Cooper PA, et al. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011;104:75-82
88. Garcia JA, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008;7:1347-1354
89. Hansel DE, Platt E, Orloff M, et al. Mammalian target of rapamycin (Mtor) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol 2010;176:3062-3072
90. Chiong E, Lee IL, Dadbin A, et al. Effects of Mtor inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res 2011;17:2863-2873
91. Vasconcelos-Nobrega C, Pinto-Leite R, Arantes-Rodrigues R, et al. In vivo and in vitro effects of RAD001 on bladder cancer. Urol Oncol 2011 [Epub ahead of print] PMID: 22169072
92. Milowsky MI, Regazzi AM, Garcia-Grossman IR, et al. Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. J Clin Oncol 2011;29(Suppl):abstract 4606
93. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: Immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010;37:473-484
94. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-2526
95. Carthon BC, Wolchok JD, Yuan J, et al. Preoperative CTLA-4 blockade: Tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010;16:2861-2871
96. Iles RK, Chard T. Human chorionic gonadotropin expression by bladder cancers: Biology and clinical potential. J Urol 1991;145:453-458
97. Morse MA, Chapman R, Powderly J, et al. Phase I study utilizing a novel antigen-presenting cell-Targeted vaccine with Toll-like receptor stimulation to induce immunity to self-Antigens in cancer patients. Clin Cancer Res 2011;17:4844-4853
98. Morse MA, Bradley DA, Keler T, et al. CDX-1307: A novel vaccine under study as treatment for muscle-invasive bladder cancer. Expert Rev Vaccines 2011;10:733-742
99. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-422
100. Levitt JM, Yamashita H, Jian W, et al. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. Mol Cancer Ther 2010;9:1128-1135
101. Metalli D, Lovat F, Tripodi F, et al. The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-Activated protein kinase-dependent activation of paxillin. Am J Pathol 2010;176:2997-3006
102. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 2010;46:1260-1270
103. Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005;23:7785-7793
104. Sridhar SS, Canil CM, Mukherjee SD, et al. Princess Margaret Hospital, Toronto, ON, Canada; Ottawa Regional Cancer Center, Ottawa, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; London Regional Cancer Centre, London, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada A phase II study of single-Agent nab-paclitaxel as second-line therapy in patients with metastatic urothelial carcinoma. Presented at the Proceedings of the 2010 Genitourinary Cancers Symposium; 2010
105. Smith DC, Grivas P, Daignault S, et al. A phase II trial of neoadjuvant ABI-007, carboplatin and gemcitabine (ACG) in patients with locally advanced carcinoma of the bladder [abstract 244]. Genitourinary cancer symposium; 2011
106. Cortes J, Montero AJ, Gluck S. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treat Rev 2012;38(2):143-151
107. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet 2011;377:914-923
108. Quinn DI, Aparicio A, Tsao-Wei DD, et al. California Cancer Consortium; University of Southern California Keck School of Medicine and Norris Comprehensive Cancer Center, Los Angeles, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Southern California, Los Angeles, CA; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; City of Hope, Duarte, CA; University of Chicago, Chicago, IL; University of California, Davis, Sacramento, CA Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)-Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial. Presented at the 2010 ASCO Annual Meeting; 2010
109. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007;18:522-528
110. Ame JC, Spenlehauer C, De Murcia G. The PARP superfamily. Bioessays 2004;26:882-893
111. Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010;2:53ra75
112. Wnek SM, Kuhlman CL, Camarillo JM, et al. Interdependent genotoxic mechanisms of monomethylarsonous acid: Role of ROS-induced DNA damage and poly(ADP-ribose) polymerase-1 inhibition in the malignant transformation of urothelial cells. Toxicol Appl Pharmacol 2011;257:1-13
113. Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol 2011;22:139-144
114. Sonpavde G, Okuno N, Weiss H, et al. Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma. Urology 2007;69:1221-1226
115. Shen SS, Smith CL, Hsieh JT, et al. Expression of estrogen receptors-Alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006;106:2610-2616
116. Rosenberg JE, Halabi S, Sanford BL, et al. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Ann Oncol 2008;19:946-950
117. Kamat AM, Karashima T, Davis DW, et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 2004;3:279-290
118. Cheung EM, Quinn DI, Tsao-Wei DD, et al. California Cancer Consortium Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy-California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial. Presented at the 2008 ASCO Annual Meeting; 2008
119. Stadler WM, Vaughn DJ, Sonpavde G, et al. Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer. J Clin Oncol 2011;29(Suppl):abstract 4567
120. Williams PD, Cheon S, Havaleshko DM, et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res 2009;69:8302-8309
121. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005;11:2625-2636
122. Takata R, Katagiri T, Kanehira M, et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci 2007;98:113-117
123. Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol 2011;22:139-144
124. Gallagher DJ, Milowsky MI, Ishill N, et al. Detection of circulating tumor cells in patients with urothelial cancer. Ann Oncol 2009;20:305-308
125. Gallagher D, Joseph V, Garcia-Grossman IR, et al. Germline single-nucleotide polymorphisms (SNPs) associated with response of urothelial carcinoma (UC) to platinum-based therapy: The role of the host. J Clin Oncol 2011;29(Suppl 7):abstract 236
126. The ALlele FREquency Database
127. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006;107:506-513
128. Sonpavde G, Galsky MD, Vogelzang NJ. First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: Should we stop separating cisplatin-eligible and -ineligible patients? J Clin Oncol 2010;28:e441-2.author reply e443-e444
129. Sonpavde G, Sternberg CN, Rosenberg JE, et al. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 2010;11:861-870
130. Sonpavde G, Rosenberg JE, Hahn NM, et al. Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma. J Clin Oncol 2010;28:e205-7.author reply e208
131. Milowsky MI, Nanus DM, Maluf FC, et al. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol 2009;27:4062-4067
132. Boukovinas I, Androulakis N, Vamvakas L, et al. Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: A multicenter phase II study of the Hellenic Oncology Research Group. Ann Oncol 2006;17:1687-1692
133. Garcia JA, Stephenson AJ, Ireland J, et al. Sunitinib in BCG-refractory non-muscle-invasive transitional cell carcinoma of the bladder. J Clin Oncol 2011;29(Suppl 7):abstract 262